Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yanqiu Lu

Showing results (51-60 of 56) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 56 results.
Microbiology Spectrum|August 4, 2021
SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic VariantsFengming Sun, Xiuhua Wang, Shun Tan, et al.
Biomaterials|September 29, 2020
Nanoparticles retard immune cells recruitment in vivo by inhibiting chemokine expressionJianxiong Xu, Jinxuan Wang, Juhui Qiu, et al.
Infectious Diseases and Therapy|June 11, 2022
Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in ChinaYihong Zhou, Yuanyuan Qin, Yanqiu Lu, et al.
Infectious Diseases and Therapy|January 20, 2022
No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort StudyYinqiu Huang, Xiaoqing He, Hui Chen, et al.
The Journal of Infection|December 29, 2021
HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?Yuanyuan Qin, Yihong Zhou, Songtao Liu, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96Bin Su, Guiju Gao, Min Wang, et al.
Pageof 6

Showing results (51-60 of 56) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 56 results.
Microbiology Spectrum|August 4, 2021
SARS-CoV-2 Quasispecies Provides an Advantage Mutation Pool for the Epidemic VariantsFengming Sun, Xiuhua Wang, Shun Tan, et al.
Biomaterials|September 29, 2020
Nanoparticles retard immune cells recruitment in vivo by inhibiting chemokine expressionJianxiong Xu, Jinxuan Wang, Juhui Qiu, et al.
Infectious Diseases and Therapy|June 11, 2022
Efficacy and Safety of Voriconazole Versus Amphotericin B Deoxycholate Induction Treatment for HIV-Associated Talaromycosis: A Prospective Multicenter Cohort Study in ChinaYihong Zhou, Yuanyuan Qin, Yanqiu Lu, et al.
Infectious Diseases and Therapy|January 20, 2022
No Statistically Apparent Difference in Antifungal Effectiveness Observed Among Trimethoprim/Sulfamethoxazole Plus Clindamycin or Caspofungin, and Trimethoprim/Sulfamethoxazole Monotherapy in HIV-Infected Patients with Moderate to Severe Pneumocystis Pneumonia: Results of an Observational Multicenter Cohort StudyYinqiu Huang, Xiaoqing He, Hui Chen, et al.
The Journal of Infection|December 29, 2021
HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?Yuanyuan Qin, Yihong Zhou, Songtao Liu, et al.
The Lancet Regional Health. Western Pacific|August 7, 2023
Efficacy and safety of ainuovirine versus efavirenz combination therapies with lamivudine/tenofovir disoproxil fumarate for medication of treatment-naïve HIV-1-positive adults: week 48 results of a randomized controlled phase 3 clinical trial followed by an open-label setting until week 96Bin Su, Guiju Gao, Min Wang, et al.
Pageof 6